Our approved medicines

The medicines listed below have marketing authorizations in the jurisdictions listed, but may not be reimbursed or available through a specific country’s health care system. For more information, please contact Medical Information.

Trademark
Generic Name
Therapy Area
Approved in the Following Countries

CASGEVY™

exagamglogene autotemcel (exa-cel)

Sickle Cell Disease

Bahrain
England
European Union
Kingdom of Saudi Arabia
Scotland
United States
Wales

CASGEVY™

exagamglogene autotemcel (exa-cel)

Transfusion-Dependent Beta Thalassemia

Bahrain
England
European Union
Kingdom of Saudi Arabia
Scotland
United States
Wales

TRIKAFTA®

elexacaftor/tezacaftor/ivacaftor and ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
Israel
Liechtenstein
New Zealand
Russia
Switzerland
United States
Uruguay

KAFTRIO® 
in a combination regimen with ivacaftor

ivacaftor/tezacaftor/elexacaftor in combination with ivacaftor

Cystic Fibrosis

European Union
Iceland
Norway
United Kingdom

SYMDEKO®

tezacaftor/ivacaftor and ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
Israel
Liechtenstein
New Zealand
Switzerland
United States

SYMKEVI® 
in a combination regimen with ivacaftor

tezacaftor/ivacaftor in combination with ivacaftor

Cystic Fibrosis

European Union
Iceland
Norway
United Kingdom

ORKAMBI®

lumacaftor/ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
European Union
Iceland
Israel
Liechtenstein
New Zealand
Norway
Russia
Switzerland
United Kingdom
United States

KALYDECO®

ivacaftor

Cystic Fibrosis

Australia
Brazil
Canada
European Union
Iceland
Israel
Liechtenstein
New Zealand
Norway
Oman
Switzerland
United Arab Emirates
United Kingdom
United States